Biopharma as a Strategic Asset: Insights

A teaser image of a fact sheet from PhRMA titled "Biopharma as a Strategic Asset: Insights"

The U.S. system of developing medicine is unique – it relies on a mix of private sector, public sector and research institutions working together. While not perfect, a dedicated set of actions to invest in innovation has helped the U.S. biopharmaceutical industry become a true strategic asset – one that drives innovation and effectively addresses major crises, as with COVID-19.

A teaser image of a fact sheet from PhRMA titled "Biopharma as a Strategic Asset: Insights"